{"entity":{"id":"nct05870319","kind":"trial","name":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","aka":[],"tldr":"A phase 3 trial of Sacituzumab tirumotecan, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients is a phase 3 interventional study registered as NCT05870319 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 376 participants enrolled, started 2023-06-26 and due to reach its primary completion in 2024-07-11. Interventions recorded: SKB264, Pemetrexed, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05870319","url":"https://clinicaltrials.gov/study/NCT05870319"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["sacituzumab-tirumotecan","pemetrexed","carboplatin","cisplatin"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05870319-n-engl-j-med-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05870319","phase":"3","setting":"A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","started":"2023-06-26","startedType":"actual","enrolled":376,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05870319/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}],"paper":[{"id":"paper-nct05870319-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-nct05870319-n-engl-j-med-2026/"}]}}